Achaogen — Healthcare Conference 2015
30 slides from Achaogen's conference presentation, Apr 15, 2015
Slide 1: Healthcare Conference, April 15, 2015
Me fe AOGCEN Nasdaq: AKAO ‘ dham Healthcare Conference April 15, 2015
Slide 2: Forward Looking Statements
* Forward Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products
Slide 3: Developing Antibacterial Medicines Targeting Growing Unmet Medical Needs
eveloping Antibacterial Medicines Targeting rowing Unmet Medical Needs e Plazomicin — lead product with strong commercial opportunity ° Targeting carbapenem-resistant Enterobacteriaceae (CRE) infections associated with high morbidity and mortality Significant commercial opportunity driven by high un
Slide 4: Pipeline
| DISCOVERY | PHASE 1 | PHASE 2 | PHASE 3 Plazomicin BSI and Pneumonia — Target pathogen Carbapenem-Resistant Enterobacteriaceae LpxC Inhibitors Target pathogens: . Pseudomonas aeruginosa & bacterial Antibody Acinetobacter baumannii Additional Gram-Negative Targets ACHAOGEN 4
Slide 5: Achaogen Leadership Team
_Achaogen Leadership Team lan Friedland, MD Chief Medical Officer © Calixa Sp merce | Kenneth Hillan, M.B., ChB | Chief Executive Officer cupist drug discovery & development and product Derek Bertocci Darcy Mootz, Ph.D. Chief Financial Officer Vice President Saccuray: Corporate Development Gencere S
Slide 6: Growing Momentum Towards Improving the Funding, Regulatory, and Commercial Prospects for Antibiotics
ng Momentum Towards Improving the Funding, ulatory, and Commercial Prospects for Antibiotic: Impact Enhanced awareness of urgent need for new antibiotics \ Additional market exclusivity Increased federal R&D funding Faster, more flexible regulatory pathways Potential for significant pricing power in
Slide 7: Expanded Plazomicin Development Plan
"Expanded Plazomicin Development Plan x — : rl ‘ « Favorable regulatory and antibiotic market developments create an attractive opportunity to improve the path to market for plazomicin « Pivotal Phase 3 study in cUTI — Single pivotal study expected to support first US approval of plazomicin ¢ Inpara
Slide 8: Phase 2 Program in Complicated UTI (cUTI) Backed by Robust Phase 2 Data
hase 3 Program in Complicated UTI (cUTI) jacked by Robust Phase 2 Data Q Protocol: Multi-national, randomized, double-blind study in complicated urinary tract infection and ica acute pyelonephritis (CUTAP) Study Drugs: Plazomicin (10 or 15 mg/kg) vs. levofloxacin (750 mg) C1 N= 145 patients By-Patie
Slide 9: Phase 3 cUTI Provides Potential for Initial US Approval in 2018
® Phase 3 cUTI Provides Potential for Initial US pproval in 2018 ~s, ‘ pe i * Single Phase 3 study in cUTI to support US approval * 15% non-inferiority margin translates to a smaller study sample size (n=~530) * Satisfies FDA-required patient safety database * Initial US label anticipated to reserve
Slide 10: Phase 3 cUTI Study Design
Phase 3 cUTI Study Design: = andomized, double blind comparator controlled with oral ._ step-down option ‘ oy? ar Plazomicin Signs / Primary Endpoint symptoms of % * Microbiological cUTI, including } Levofloxacin eradication + clinical AP* cure Meropenem e Single global Phase 3 study ° Goal is to op
Slide 11: Significant Opportunity for Plazomicin to Address Limited Treatment Options
® Significant Opportunity for Plazomicin to Address Limited treatment options for patients with CRE UTI infections « Infectious disease (ID) physicians estimate CRE UTIs have significant morbidity and mortality’ Risk of progression to urosepsis is a key concern? ¢ Significant ID physician interest i
Slide 12: Anticipated US Plazomicin cUTI Label
"Anticipated US Plazomicin cUTI Label Label Section 1: Indications Usage Label Section 12 Microbiology Commercially Favorable Anticipated Label Statement: + Asonly limited clinical safety and efficacy data are currently available, reserve plazomicin for use in patients who have limited or no alterna
Slide 13: Plazomicin is Differentiated from Key Late-Stage CRE Competitors
®Plazomicin is Differentiated from Key Late-Stage CRE Competitors ~~ Drug / Company | Description el reel ay! IV aminoglycoside Achaogen IV BUBLI Avycaz/ (ceftazidime + Approved 2/25/15 AZ & Actavis Asean . Phase 3 Eravacycline f j\jorai tetracycline (one study Tetraphase ne Carbavance/ IV BUBLI The
Slide 14: Strong Infectious Disease Physician Interest in Prescribing Plazomicin
trong Infectious Disease Physician Interest in rescribing Plazomicin . Clinical data from CARE and cUTI study available Physician Adoption Estimates' Physician Responses to cUTI Range Based on Potential CARE Efficacy Outcomes + CARE Product Profile’ 50% "Novel agent with superior efficacy and antimi
Slide 15: Substantial Addressable Patient Population
tantial Addressable Patient Population ected and Confirmed CRE opportunity in multiple infection US and EU-5 Estimated Inpatient Cases in 2014 Confirmed CRE Opportunity (5-14 days of therapy) 73% UTI ~ 13% Pneumonia 14% BSI Total Inpatients 11.8M Suspected CRE Opportunity (1-3 days of therapy) Pneum
Slide 16: Carbapenem Resistance in Klebsiella spp.
Percentage of Isolates Nonsusceptible ACHAOGEN Carbapenem Resistance in Klebsiella spp. Greece EU-5 sources ors 2.eu8 Seuss: ‘Curve extrapolated fom multiple datasources "20042010: The Sursilance Network database US Aas published in Braykovet. al. 2018 (Mebsb la preutonge) * 2011: Aetivierob Agents
Slide 17: Plazomicin is Well-Positioned for Value-Based Pricing with cUTI Label
*lazomicin is Well-Positioned for Value-Based Pricing with cUTI Label SARE provides pricing upside Few Therapeutic No agents approved for CRE infections of any type; existing therapies colistin and Options tigecycline have limitations * Limited use label supports usage in patients with highest unmet
Slide 18: Changes in External Landscape Supportive of Move to Value-Based Pricing
Shanges in External Landscape Supportive of love to Value-Based. Pricing ¢ Increased receptivity among key stakeholders to new pricing paradigm — In 2013 Pew Trusts Forum, panelists from FDA, pharma, and payers generally agreed that the narrow market established by a limited population pathway sets
Slide 19: cUTI Trial Drives the Biggest Percentage of the Estimated Plazomicin Revenue
TI Trial Drives The Biggest Percentage of the Estimated Percentage of Plazomicin Revenue By Infection Type Usage for Suspected and Confirmed CRE Launch Year Peak Revenue Year ~30% Growth in CRE Prevalence ACHAOGEN
Slide 20: Plazomicin Phase 3 cUTI Trial Key Development Milestones
®Plazomicin Phase 3 cUTI Trial ‘ey Development Milestones Saas ° Key milestones — 2015 Q4 : Open sites for enrollment — 2017 H2 : Topline results — 2017 H2 : NDA submission ° Phase 3 trial cost estimate of $45 to $50 million ¢ Potential to leverage non-dilutive funding — Additional funding possible
Slide 21: Phase 3 CRE Study Design
hase 3 CRE Study Design thogen-specific, randomized,-open-label, active comparator controlled ComBatTinG ANTIBIOTIC- Resistant EE wrerosacteriacear Primary Endpoint Presumed or . * 28 day mortality plus severe Documented disease related complications CRE Infection (Bloodstream i Secondary Endpoints
Slide 22: Improving Enrollment in the CARE Study
mproving Enrollment in the CARE Study Protocol Engagement Resourcing Number/Mix u u u Local Add study Expand / Presence coordinators optimize mix ACHAOGEN gait Eligibility Procedures Optimize Endpoint | | | Better measure of treatment effect 22 Expand Simplify
Slide 23: Targeting Initial Registration Based on cUTI
argeting Initial Registration Based on cUTI « cUTI study expected to serve as pivotal study supporting US registration « CARE study provides supplemental data in CRE patients with BSI and pneumonia > supports potential sNDA « sNDA is dependent on patient enrollment and positive top-line data ACHAOGE
Slide 24: Discovery Engine
Discovery Engine Two lead preclinical programs targeting gram-negative bacterial infections ¢ LpxC inhibitor « Antibody program
Slide 25: LpxC Inhibitors: Novel Mechanism of Action with Significant Potential
xC Inhibitors: Novel Mechanism of Action with ignificant Potential — C) New class of bactericidal antibiotics — LpxC is an essential enzyme in vitro Activity vs. Clinical Isolates of P. aeruginosa required for outer membrane synthesis in gram-negative bacteria - Potent activity vs. R aeruginosa — No
Slide 26: Therapeutic Antibody Program
apeutic Antibody Program . Initial target candidate profile: Monotherapy treatment for serious gram-negative infections Sf Hypothesis-driven approach focused on functionally important targets on the bacterial cell surface (targets not being disclosed at this time) 5 Potential benefits: © Direct bact
Slide 27: Upcoming Milestones: Plazomicin and Research Programs
e Plazomicin — Phase 3 cUT] initiation Q4 2015 — Projected cUTI top-line results and NDA filing H2 2017 — Projected CARE sNDA H2 2018 e Research Programs — Investigational new drug application (“IND”) - 2016 — Proof of concept for therapeutic antibody ACHAOGEN a
Slide 28: Financial Snapshot
*: nancial Snapshot-. ——— EEE ||ELLTLT e Listed on NASDAQ March 2014 Shares NASDAQ AKAO - Top Insti ional Shareholder (12/31/2014) RSE | symbol: aS Fidelity Management & Research Company | 2,630 Market Cap (as of 04/10/2015). $132M Domain associated CEE: AAO Shares o/s (as of 12/31/2014): 17.9M Venr
Slide 29: Where We Are Today
ere We Are Today — ® Harnessing regulatory and legislative tailwinds to bring plazomicin to patients & value to investors * Revised plazomicin development plan offers strong commercial opportunity in patients with CUTI, BSI, or pneumonia caused by CRE ° Enhanced NPV based on pricing and commercial a
Slide 30: Achaogen
SF ACHAOGEN